Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Joint Analysis of Data From NCCTG N9831 and NSABP B-31
      QxMD      Google Scholar   
Citation:
J Clin Oncol vol 29 (25) 3366-3373
Year:
2011
Type:
Manuscript
Funding:
NCTN
Endpoint:
Primary
Analysis:
Long-Term-Followup
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
pmc-release
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Book Volume:
1
Parents:
549  
Children:
None
Program:
OGC
Primary Committee:
Breast
Sec. Committees:
   
Pharmas:
 
Grants:
U10 CA012027, R01-CA129949, U10 CA069651, U10-CA69651, R01 CA129949, U10 CA069974, U10-CA25224, U10-CA37377, U10 CA025224, U10-CA12027, U10 CA037377  
Corr. Author:
 
Authors:
                     
Networks:
 
Study
NCCTG-N9831
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
3
Keywords:
Bc5, Bc6, Original Reports, Breast Cancer